BIBR1532 is a potent and selective telomerase inhibitor with IC50 of 93 nM. The selectivity of BIBR1532 was assessed in a panel of DNA and RNA polymerases, including HIV reverse transcriptase, showing that none of these enzymes was inhibited at concentrations vastly exceeding the IC50 for telomerase.
 |
Source | Target Oncol (2015). Figure 3. BIBR1532 |
| Method | cell apoptosis assay | |
| Cell Lines | MCF-7 cells | |
| Concentrations | 10 μM | |
| Incubation Time | 24 h | |
| Results | The drug combination induced 28.67±2.03 % apoptosis, which is significantly higher than apoptosis caused by 20 μM BIBR1532 alone. |
 |
Source | Target Oncol (2015). Figure 2. BIBR1532 |
| Method | colony formation assay | |
| Cell Lines | MCF-7 cells | |
| Concentrations | 10 μM | |
| Incubation Time | 72 h | |
| Results | BIBR1532 and paclitaxel alone inhibited cell colony formation in a dose-dependent manner in MCF-7 cells. |
| Cell Experiment | |
|---|---|
| Cell lines | JVM13 cells |
| Preparation method | Telomerase activity measurements. Telomerase activity of cell populations was determined using the TeloTaGGG polymerase chain reaction enzyme-linked immunosorbent assay (PCR ELISAPLUS) kit (Roche, Mannheim, Germany) according to the manufacturer’s protocol (telomeric repeat amplification protocol [TRAP] assay). Heat-treated cellular lysates (85°C for 10 minutes) were used as negative controls for each sample. Samples are considered as telomerase positive if the difference in absorbance is higher than 2-fold background activity. WST-1 assays Cells (0.5 to 5*104) were plated as triplicates in complete RPMI 1640 medium with various concentrations of BIBR1532. After 24 to 72 hours, water-soluble tetrazolium (WST-1) (Roche) was added, which is transformed into formazan by mitochondrial reductase systems. The increase in the number of viable cells results in an increase of activity of mitochondrial dehydrogenases, leading to an increase of formazan dye formed, which was quantified by ELISA reader after 2, 3, and 4 hours of incubation. |
| Concentrations | 0 ~ 80 μM |
| Incubation time | 24 or 72h |
| Animal Experiment | |
|---|---|
| Animal models | Human MM xenograft murine model in CB 17 SCID-mice |
| Formulation | phosphate-buffered saline (PBS) |
| Dosages | 35 mg/kg daily |
| Administration | intraperitoneally |
| Molecular Weight | 331.36 |
| Formula | C21H17NO3 |
| CAS Number | 321674-73-1 |
| Solubility (25°C) | DMSO 60 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related Checkpoint Products |
|---|
| CBP501 Affinity Peptide
CBP501 Affinity Peptide is a Chk kinase inhibitor that can abrogate G2 arrest induced by DNA-damaging agents. |
| Chktide
Chktide is a substrate for CHK1 and CHK2. |
| Zn-DPA-maytansinoid conjugate 1
Zn-DPA-maytansinoid conjugate 1 is a small molecule-based maytansinoid conjugate targeting immune checkpoint. |
| CHK1-IN-7
CHK1-IN-7 is a potent human CHK1 inhibitor. |
| Chk2-IN-1
Chk2-IN-1 (compound 1) is a potent and selective inhibitor of checkpoint kinase 2 (Chk2), with IC50s of 13.5 nM and 220.4 nM for Chk2 and Chk1, respectively. Chk2-IN-1 can elicit a strong ataxia telangiectasia mutated (ATM)-dependent Chk2-mediated radioprotection effect. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
